Advertisement
Advertisement
NMRA
Neumora Therapeutics, Inc. Common Stock
1.64
USDSponsored
+0.03
+1.86%
Aug 03, 15:58 UTC -4
Closed
After-Market
1.64
0.00
0.00%
NMRA Earnings Reports
Positive Surprise Ratio
NMRA beat 6 of 11 last estimates.
55%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.24
Implied change from Q1 26 (Revenue/ EPS)
--
/-20.00%
Implied change from Q2 25 (Revenue/ EPS)
--
/-27.27%
Neumora Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, NMRA reported earnings of -0.30 USD per share (EPS) for Q1 26, beating the estimate of -0.31 USD, resulting in a 5.12% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -16.74% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an decrease of -20.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicycle Therapeutics plc - ADR
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.58
Actual
-$0.72
Surprise
-22.64%
Compugen Ltd
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Vertex Pharmaceuticals Inc
Report Date
Aug 03, 2026 For Q2 26
Estimate
$4.82
Actual
$4.73
Surprise
-1.95%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Krystal Biotech, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
$1.68
Actual
$1.79
Surprise
+6.00%
TG Therapeutics, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$0.33
Actual
$0.05
Surprise
-84.97%
Twist Bioscience Corporation Common Stock
Report Date
Aug 03, 2026 For Q3 26
Estimate
-$0.50
Actual
-$0.56
Surprise
-11.20%
Disc Medicine, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.78
Actual
-$1.54
Surprise
+13.63%
FAQ
What were Neumora Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 5.12%, and revenue of $0.00, 0% as expectations.
How did the market react to Neumora Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -16.74%, changed from $2.33 before the earnings release to $1.94 the day after.
When is Neumora Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Neumora Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement